Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake.

Tirzepatide (mounjaro) was significantly more effective in reducing HbA1c and body weight than the selective GLP-1 RA semaglutide (ozempic).

Both drugs caused similar reductions in appetite, although tirzepatide caused greater weight loss.

contact us now for further information

info@weightloss